This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
5two
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Peroxisome proliferator-activated receptor gamma lignad binding domain in complex with a novel selectively PPAR gamma-modulating ligand VSP-51== | |
| + | <StructureSection load='5two' size='340' side='right' caption='[[5two]], [[Resolution|resolution]] 1.93Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[5two]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5TWO OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5TWO FirstGlance]. <br> | ||
| + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=7MV:N-BENZYL-1-[(4-CHLORO-3-FLUOROPHENYL)METHYL]-1H-INDOLE-5-CARBOXAMIDE'>7MV</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5two FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5two OCA], [http://pdbe.org/5two PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5two RCSB], [http://www.ebi.ac.uk/pdbsum/5two PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5two ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | == Disease == | ||
| + | [[http://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:[http://omim.org/entry/601665 601665]]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.<ref>PMID:9753710</ref> Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:[http://omim.org/entry/604367 604367]]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.<ref>PMID:12453919</ref> <ref>PMID:11788685</ref> Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:[http://omim.org/entry/137800 137800]]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility. | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.<ref>PMID:9065481</ref> <ref>PMID:16150867</ref> <ref>PMID:20829347</ref> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Thiazolidinediones (TZD) function as potent anti-diabetic drugs through their direct action on the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma), but their therapeutic benefits are compromised by severe side effects. To address this concern, here we developed a potent "hit" compound, VSP-51, which is a novel selective PPARgamma-modulating ligand with improved therapeutic profiles in vitro compared to the multi-billion dollar TZD drug rosiglitazone (Rosi). Unlike Rosi, VSP-51 is a partial agonist of PPARgamma with improved insulin sensitivity due to its ability to bind PPARgamma with high affinity without stimulating adipocyte differentiation and the expression of adipogenesis-related genes. We have determined the crystal structure of the PPARgamma ligand-binding domain (LBD) in complex with VSP-51, which revealed a unique mode of binding for VSP-51 and provides the molecular basis for the discrimination between VSP-51 from TZDs and other ligands such as telmisartan, SR1663 and SR1664. Taken together, our findings demonstrate that: a) VSP-51 can serve as a promising candidate for anti-diabetic drug discovery; and b) provide a rational basis for the development of future pharmacological agents targeting PPARgamma with advantages over current TZD drugs. | ||
| - | + | Identification of a novel selective PPARgamma ligand with a unique binding mode and improved therapeutic profile in vitro.,Yi W, Shi J, Zhao G, Zhou XE, Suino-Powell K, Melcher K, Xu HE Sci Rep. 2017 Jan 27;7:41487. doi: 10.1038/srep41487. PMID:28128331<ref>PMID:28128331</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | + | </div> | |
| - | + | <div class="pdbe-citations 5two" style="background-color:#fffaf0;"></div> | |
| - | + | == References == | |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
[[Category: Melcher, K]] | [[Category: Melcher, K]] | ||
| - | [[Category: Yi, W]] | ||
[[Category: Shi, J]] | [[Category: Shi, J]] | ||
| - | [[Category: Zhao, G]] | ||
[[Category: Suino-Powell, K]] | [[Category: Suino-Powell, K]] | ||
| + | [[Category: Xu, H E]] | ||
| + | [[Category: Yi, W]] | ||
| + | [[Category: Zhao, G]] | ||
| + | [[Category: Zhou, X E]] | ||
| + | [[Category: Dna binding protein]] | ||
| + | [[Category: Lignad binding domain]] | ||
| + | [[Category: Peroxisome proliferator-activated receptor gamma]] | ||
| + | [[Category: Selective ppar gamma ligand]] | ||
| + | [[Category: Transcription]] | ||
| + | [[Category: Vsp-51]] | ||
Revision as of 09:28, 10 March 2017
Peroxisome proliferator-activated receptor gamma lignad binding domain in complex with a novel selectively PPAR gamma-modulating ligand VSP-51
| |||||||||||
